

1 **Generalizability of Tau and Amyloid Plasma Biomarkers in Alzheimer’s Disease Cohorts of Diverse**
2 **Genetic Ancestries**

3
4 Anthony J. Griswold^{1,2*}, Farid Rajabli^{1,2}, Tianjie Gu¹, Jamie Arvizu¹, Charles G. Golightly¹, Patrice L.
5 Whitehead¹, Kara L. Hamilton-Nelson¹, Larry D. Adams¹, Jose Javier Sanchez¹, Pedro R. Mena¹, Takiyah
6 D. Starks³, Maryenela Illanes-Manrique⁴, Concepcion Silva⁵, William S. Bush^{6,7}, Michael L. Cuccaro^{1,2},
7 Jeffery M. Vance^{1,2}, Mario R Cornejo-Olivas⁴, Briseida E. Feliciano-Astacio⁵, Goldie S. Byrd³, Gary W.
8 Beecham^{1,2}, Jonathan L. Haines^{6,7}, and Margaret A. Pericak-Vance^{1,2}

- 9
10 1) John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, 33136, USA;
11 2) Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL,
12 33136, USA;
13 3) Maya Angelou Center for Health Equity, Wake Forest University, Winston-Salem, NC, 27102, USA;
14 4) Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, 15003, Peru;
15 5) Department of Internal Medicine, Universidad Central Del Caribe, Bayamón, Puerto Rico, 00960, USA;
16 6) Department of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland,
17 OH, 44106, USA;
18 7) Cleveland Institute for Computational Biology, Cleveland, OH, 44106, USA;

19
20
21 *Corresponding Author:

22 Anthony J. Griswold, Ph.D.
23 Associate Professor of Human Genetics
24 The Dr. John T. Macdonald Foundation Department of Human Genetics
25 John P. Hussman Institute for Human Genomics
26 University of Miami Miller School of Medicine
27 1501 NW 10th Avenue (M-860), BRB 318
28 Miami, FL 33136
29 (305) 243-5982 (office)
30

31 **Abstract**

32

33 **Introduction.** Plasma phosphorylated threonine-181 of Tau and amyloid beta are biomarkers for
34 differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk
35 across diverse populations, generalizability of existing biomarker data is not assured.

36 **Methods.** In 2,086 individuals of diverse genetic ancestries (African American, Caribbean Hispanic, and
37 Peruvians) we measured plasma pTau-181 and A β 42/A β 40. Differences in biomarkers between cohorts
38 and clinical diagnosis groups and the potential discriminative performance of the two biomarkers were
39 assessed.

40 **Results.** pTau-181 and A β 42/A β 40 were consistent across cohorts. Higher levels of pTau181 were
41 associated with AD while A β 42/A β 40 had minimal differences. Correspondingly, pTau-181 had greater
42 predictive value than A β 42/A β 40, however, the area under the curve differed between cohorts.

43 **Discussion.** pTau-181 as a plasma biomarker for clinical AD is generalizable across genetic ancestries,
44 but predictive value may differ. Combining genomic and biomarker data from diverse individuals will
45 increase understanding of genetic risk and refine clinical diagnoses.

46 **Background**

47 Alzheimer disease (AD) is a progressive and devastating neurodegenerative condition with a
48 prevalence of 5% in individuals 65-74 years of age, increasing to 33% by 85 years of age. This
49 corresponds to 6.7 million people in the US with a current diagnosis of AD, which is estimated to
50 increase to 14 million by 2060.[1] AD has a global impact, with diverse populations around the world
51 affected, but ancestrally diverse groups such as African American (AA) and Hispanic (HI) populations
52 are underrepresented in AD genomic and translational studies[2-11] which in part contributes to health
53 disparities in the US. Compared to Non-Hispanic White (NHW) populations AA populations have higher
54 frequencies of risk factors for complex diseases such as AD, more limited access to health services,
55 poorer health outcomes, and lower life expectancies[12-17] For example, Caribbean HI are twice as likely
56 as non-Hispanic Whites (NHW) to have late-onset AD[18,19] and the incidence of new AD cases in
57 Caribbean HI families is three times the incidence in NHW families.[20] Similarly, compared with NHW
58 individuals, individuals of African ancestry, even from the same local community, are twice as likely to
59 develop AD due to both genetic and environmental influences.[19]

60 In part, these disparities can be attributed to access to and affordability of AD diagnostic tools
61 such as magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and
62 cerebrospinal fluid (CSF) assays that can be incorporated as criteria for pre-clinical AD diagnosis.[21]
63 Therefore, the use of AD plasma biomarkers have begun wide use to assist in clinical diagnosis and refine
64 the preclinical stages of AD and MCI.[22-24] These blood-based biomarkers can be used to estimate the
65 underlying biological changes associated with AD diagnosis and prognosis including amyloid deposition
66 (plasma A β 42/A β 40 ratio)[25] and tau hyperphosphorylation and tangles (phosphorylated Tau).[26,27]

67 Critically, however, individuals of African and HI ancestry are underrepresented in most research
68 studies[7-9] including genomic and translational studies,[11,28,29] and particularly for those utilizing AD
69 plasma biomarkers.[30,31] Thus, diverse ancestral groups may not benefit to the same degree as NHW
70 from the clinical applications of genomic and biomarker studies [32-37]. While recent studies have

71 increased representation of African Americans[30,38] and Hispanics,[39,40] the sample sizes of diverse
72 individuals remain a small proportion of the total study cohorts making conclusive statements on the
73 generalizability of these findings difficult.

74 To address the issues of lack of representation of diverse ancestries in AD biomarker studies,
75 potential differences in AD biomarkers across populations, and the generalizability of AD biomarkers to
76 discriminate between clinically diagnosed AD and cognitively unimpaired (CU) individuals, herein we
77 measured plasma AD related biomarkers pTau-181 and A β 42/A β 40 ratio in a large cohort of individuals
78 representing diverse ancestral backgrounds. In these clinically diagnosed cohorts, we compare biomarker
79 concentration between those diagnosed with AD, mild cognitive impairment (MCI), CU across and within
80 the groups. Furthermore, we explore the ability of these biomarkers to discriminate between AD and CU
81 in these diverse sets of individuals. As such, we can better understand the generalizability and utility of
82 these lower-cost and readily available biomarkers for broad use in AD diagnostics in individuals of
83 diverse genetic ancestry.

84

85 **Methods**

86 *Ascertainment of Study Participants*

87 Individuals for this study have been ascertained through multiple studies of AD genetics across
88 several sites focused on individuals from underrepresented populations including self-identified Black
89 Americans of African ancestry and Hispanics (Puerto Ricans, Cuban Americans, and Peruvians). The
90 study sites include: the University of Miami (Miami, FL, USA), Wake Forest University (Winston-Salem,
91 NC, USA), Case Western Reserve University (Cleveland, OH, USA), Universidad Central del Caribe
92 (Bayamon, PR, USA), and Instituto Nacional de Ciencias Neurologicas (Lima, Peru). All participants or
93 their proxy provided written informed consent as part of the study protocols approved by the site-specific
94 Institutional Review Boards.

95 Ascertainment protocols were consistent across sites and clinical data assessments capture
96 sociodemographic information, medical and family history, dementia staging, AD/dementia symptoms,

97 neuropsychological abilities, functional capabilities, and behavioral impairments. Best-estimate diagnoses
98 were generated by a consensus committee consisting of a board-certified neurologist, a physician
99 specializing in dementia, and clinical neuropsychologists, all with expertise in adjudication of
100 AD/dementia. Using all available clinical information, participants were assigned best-estimate clinical
101 diagnoses (AD, MCI, or CU) based on criteria adapted from NIA-Alzheimer's Association
102 criteria.[21,41,42]

103 *Genotyping and Assessment of Genetic Ancestry*

104 2,086 total participants were included in this study and classified based on their self-reported
105 race-ethnicity and country of origin as African American (AA), Caribbean Hispanic (Puerto Rican or
106 Cuban American), or Peruvian (PE). For each participant, whole genome genotyping array data on the
107 Illumina Global Screening Array (Illumina, San Diego, CA, USA) was generated. Genotype markers
108 were quality controlled to include only those with high call rate (over 97%) and minor allele frequency
109 over 0.05 within each population. Genetic relatedness was evaluated using the GENESIS R package.[43]
110 Frist, the KING-Robust kinship coefficient estimator was used to calculate the KING matrix that includes
111 pairwise relatedness and measures of pairwise ancestry divergence.[44] The PC-AiR method used
112 ancestry divergence from KING-Robust estimate to perform PCA, which then was used by PC-Relate to
113 estimate pairwise kinship coefficients. Genetically related individuals with closer than 4th-degree relatives
114 were identified and only one sample per related group was retained in the analysis. Subsequently, PC-Air
115 was applied to calculate global ancestry using four reference populations were used including AI, EU,
116 AF, and EA from Human Genome Diversity Project (HGDP) data for the reference populations.[45]
117 Admixture proportions were estimated using a model-based clustering algorithm was performed as
118 implemented in the ADMIXTURE software[46] with K=4 for the reference populations.

119 *Measurement of Plasma AD Biomarkers*

120 Whole blood tubes were collected from the 2,086 participants at the time of study entry by trained
121 phlebotomists. Plasma was isolated from EDTA tubes via centrifugation, aliquoted into polypropylene

122 tubes, and stored at -80°C until further analysis. For a set of African American participants, coagulation
123 was performed in the tube and thus serum was the only available blood fluid available. Plasma/serum
124 concentrations of pTau-181, Aβ42, and Aβ40 were measured using SIMOA chemistry implemented on
125 the Quanterix HD-X analyzer (Quanterix, Billerica, MA, USA)[47] according to manufacturer's
126 instructions for the pTau-181 Advantage V2 assay and Neurology 3-Plex A assay. Samples were
127 randomized according to age (at time of blood collection), sex, and diagnosis and assayed in duplicate on
128 each Simoa plate. Initial data analysis was performed using the Quanterix Analyzer v1.6 software to
129 calculate standard curves and biomarker concentrations. After quality control including removing of
130 related participants, failed biomarker assays, and removal of outliers greater than three standard
131 deviations from the mean 1,368 participants with plasma and 721 participants with serum remained in the
132 analyses (Table 1).

133

134 **Table 1. Characteristics of the study participants and biomarker levels**

Plasma Samples				
Alzheimer's Disease	All samples (N=421)	African American (N=71)	Caribbean Hispanic (N=312)	Peruvian (N=38)
Sex				
Female	283 (67.2%)	47 (66.2%)	209 (67.0%)	27 (71.1%)
Male	138 (32.8%)	24 (33.8%)	103 (33.0%)	11 (28.9%)
Age (years)				
Mean (SD)	79.4 (7.85)	80.0 (8.48)	79.3 (7.76)	79.8 (7.59)
pTau181 level (pg/mL)				
Mean (SD)	2.76 (1.81)	3.00 (1.49)	2.68 (1.87)	3.08 (1.81)
Aβ42/40				
Mean (SD)	0.0410 (0.0137)	0.0478 (0.0159)	0.0402 (0.0130)	0.0352 (0.00990)
Mildly Cognitive Impaired	All samples (N=270)	African American (N=88)	Caribbean Hispanic (N=182)	Peruvian (N=0)
Sex				-
Female	193 (71.5%)	67 (76.1%)	126 (69.2%)	-
Male	77 (28.5%)	21 (23.9%)	56 (30.8%)	-
Age (years)				-
Mean (SD)	74.9 (7.36)	72.7 (7.36)	75.9 (7.15)	-
pTau181 level (pg/mL)				-
Mean (SD)	1.91 (1.26)	1.90 (1.46)	1.92 (1.15)	-
Aβ42/40				-
Mean (SD)	0.0455 (0.0149)	0.0536 (0.0168)	0.0418 (0.0123)	-
Cognitively Unimpaired	All samples (N=677)	African American (N=234)	Caribbean Hispanic (N=355)	Peruvian (N=88)
Sex				
Female	533 (78.7%)	197 (84.2%)	270 (76.1%)	66 (75.0%)
Male	144 (21.3%)	37 (15.8%)	85 (23.9%)	22 (25.0%)
Age (years)				
Mean (SD)	73.2 (7.23)	70.9 (6.73)	74.7 (7.36)	72.9 (6.41)
pTau181 level (pg/mL)				
Mean (SD)	1.98 (2.60)	2.02 (4.15)	1.84 (1.05)	2.40 (1.22)
Aβ42/40				
Mean (SD)	0.0477 (0.0247)	0.0575 (0.0196)	0.0432 (0.0275)	0.0408 (0.0138)

135

136

137

African American Serum Samples

	CU (N=370)	MCI (N=103)	AD (N=248)	Overall (N=721)
Sex				
Female	275 (74.3%)	81 (78.6%)	194 (78.2%)	550 (76.3%)
Male	95 (25.7%)	22 (21.4%)	54 (21.8%)	171 (23.7%)
Age (years)				
Mean (SD)	69.5 (6.74)	73.6 (7.03)	80.8 (8.12)	74.0 (8.89)
pTau181 level (pg/mL)				
Mean (SD)	1.50 (1.46)	1.18 (1.22)	2.69 (2.26)	1.86 (1.85)
Aβ42/40				
Mean (SD)	0.0542 (0.113)	0.0481 (0.0182)	0.0491 (0.0458)	0.0519 (0.0899)

138

139 *Biomarker Statistical Analysis*

140 Biomarker concentrations were log₁₀-transformed to satisfy normality assumptions in the
 141 downstream analysis. The differences in biomarker levels across ancestral groups and between AD, MCI
 142 and CU individuals was analyzed using a linear regression model adjusted for age, sex, and population
 143 substructure (principal components 1-3) followed by the post hoc least significant difference test for
 144 pairwise group comparison and adjusted for multiple comparisons by Bonferroni.

145 To assess the diagnostic performance and construct receiver operator characteristic (ROC) curves,
 146 we employed three logistic regression models: pTau-181 concentration alone, Aβ42/Aβ40 alone, and
 147 pTau-181 concentration and Aβ42/Aβ40 together. For this analysis we used only individuals having data
 148 available on both pTau-181 and Aβ42/Aβ40 biomarkers (N = 1,298 for plasma, N = 260 for serum). Area
 149 under the curves (AUC) of the three models were compared using the DeLong test and adjusted for
 150 multiple comparisons (Bonferroni). All analysis were performed using R v.4.1.1 with packages:
 151 lmerTest,[48] multcomp,[49] lsmeans,[50] and pROC,[51] and visualizations created with ggpubr.[52]

152 **Results**

153 *Global Genetic Ancestry of Participants*

154 As detailed in Table 1, the participants in this study were ascertained as part of four distinct
 155 cohorts: African American (AA), and HI with origins from the Caribbean (CH - Puerto Rican or Cuban

156 American) or Peru (PE). Figure 1A illustrates principal component analysis results of the study samples
157 and four continental populations from the HGDP reference panel. Genomic admixture varied widely
158 across cohorts with respect to proportions of European, African, Amerindian, and East Asian ancestries
159 (Figure 1B). Given similarity of ancestral admixture between Puerto Ricans and Cuban Americans and
160 the relatively small sample size of Cuban Americans, these cohorts were combined in further analysis as
161 Caribbean Hispanics. Global ancestry analysis confirmed primarily two-way admixture in AA (African
162 and European), three-way admixture in CH (African, European, and Amerindian), and four-way
163 admixture in PE (African, European, Amerindian, and East Asian) with a high proportion of Amerindian
164 background.

165 *Plasma pTau-181 and A β 42/A β 40 ratios across ancestries*

166 We first set out to determine how AD plasma biomarker levels of pTau-181 and A β 42/A β 40
167 compare across ancestries, within each diagnostic category of AD or CU. In general, plasma pTau-181
168 concentrations were consistent across these populations. There was a modest but significant increase in
169 Peruvian controls relative to the other two groups ($p=0.02$ vs. AA, $p=0.002$ vs. CH), Figure 2A), but
170 among AD there were no significant differences between groups (Figure 2B). The A β 42/A β 40 ratio was
171 significantly higher in African Americans relative to the other two groups in the CU comparison
172 $p=2.38 \times 10^{-7}$ vs. Peruvian, $p=4.36 \times 10^{-7}$ vs. CHI, Figure 2C) and also trending higher in AD with a
173 significant difference between AA and CH ($p = 0.05$, Figure 2D).

174 *Plasma pTau-181 and A β 42/A β 40 comparisons*

175 Plasma pTau-181 concentrations were significantly increased in individuals with diagnosed
176 clinical AD compared to CU and MCI ($p = 1.67 \times 10^{-13}$, Figure 3A) considering all individuals across all
177 cohorts (Figure 3A). When analyzing each cohort separately, plasma pTau-181 concentrations were
178 significantly higher in AD vs CU in AA ($p = 1.88 \times 10^{-8}$, Figure 3B) and CH ($p = 3.13 \times 10^{-7}$, Figure 3D)
179 with a trend that did not reach statistical significance for Peruvians ($p = 0.07$, Figure 3C). When
180 considering AD vs MCI, there was again a statistically higher pTau-181 concentration in overall ($p =$
181 7.83×10^{-8} , Figure 3A) as well AA ($p = 7.95 \times 10^{-5}$, Figure 3B) and CH ($p = 5.25 \times 10^{-5}$, Figure 3D). The

182 plasma A β 42/A β 40 ratio was significantly lower in AD of AA relative to CU ($p = 0.02$, Figure 4A-D).
183 There was no statistically significant difference in the concentration of pTau-181 nor A β 42/A β 40 ratio
184 between MCI and CU when considering all data together or when looking at specific cohorts individually.

185 *Serum pTau-181 and A β 42/A β 40 comparisons*

186 We analyzed the biomarkers in a subset of African ancestry individuals for whom only serum,
187 rather than plasma, was available. We first evaluated potential differences between serum and plasma
188 pTau-181 and A β 42/A β 40 ratio within each diagnostic category for African Americans. Plasma pTau-181
189 concentration was higher than serum in both CU ($p = 9.16 \times 10^{-6}$, Figure 5A) and AD ($p = 1.63 \times 10^{-3}$,
190 Figure 5B). The A β 42/A β 40 ratio was lower in serum in both CU ($p = 2.44 \times 10^{-13}$, Figure 5C) and AD (p
191 $= 0.05$, Figure 5D). Given these differences, we performed analysis within these serum samples
192 separately. Like the plasma analysis, serum pTau-181 concentrations were significantly increased in
193 individuals with diagnosed clinical AD compared to either CU or MCI (Figure 6A). Also, the serum
194 A β 42/A β 40 ratio did not significantly differ (Figure 6B).

195 *Discriminatory analysis of plasma and serum pTau-181 and A β 42/A β 40*

196 We used logistic regression models to assess the accuracy of plasma and serum pTau-181
197 concentration and A β 42/A β 40 ratio in predicting clinical disease status. We evaluated the performance of
198 each biomarker individually and then in combination using the area under the receiver operating
199 characteristic curve (AROC) for each model (Figure 7). In general, pTau-181 was better at predicting
200 status than A β 42/A β 40 ratio, and the classification improved slightly when both biomarkers were used
201 together. Notably, the accuracy varies over the individual cohorts with combined AROC ranging from
202 0.85 in plasma measurements for African Americans to 0.65 in Peruvians.

203 **Discussion**

204 Herein, we have performed the largest to date study of plasma biomarkers in diverse ancestral AD
205 cohorts. Importantly, we found that the plasma concentrations of pTau-181 are generally consistent across
206 populations within clinical diagnostic categories, with a small elevation in Peruvian CU relative to
207 African Americans and Caribbean Hispanics, while the A β 42/A β 40 ratio was higher in African American

208 AD and CU cohorts relative to Peruvians or Caribbean Hispanics. Moreover, we found that the
209 plasma/serum concentration of pTau-181 was significantly greater in AD relative to CU and MCI across
210 these diverse ancestral cohorts. We did not detect differences between the statuses when comparing the
211 A β 42/A β 40 ratio across or within the cohorts. These correspond to pTau-181 offering strong predictive
212 value of AD status in these data, with A β 42/A β 40 adding little more to the model. Interestingly, however,
213 the predictive values varied widely across the ancestral groups ranging from 0.85 (AA) to 0.65 (PE).

214 The pTau-181 results generally reflect work done in previous large cohort studies done primarily
215 in European non-Hispanic White (NHW) individuals showing it to be strongly associated with AD
216 status[27]. Here we demonstrate generalizability of the pTau-181 biomarker in large cohorts of clinically
217 diagnosed individuals without stratification by alternative biomarkers such as PET imaging as had
218 previously been described for NHW.[53] Conversely, the A β 42/A β 40 ratio did not offer strong
219 association with AD status despite several previous reports of this association. While we cannot dismiss
220 the possibility that this is due to either ancestral diversity or the clinical diagnosis used in this study, it has
221 been previously shown that the SIMOA chemistry assays for these analytes may lack the sensitivity
222 required to detect such differences [54]. In biomarker studies of more diverse individuals, the utility of
223 pTau-181 has been shown in predicting AD status in Caribbean Hispanics[39] as well as African
224 Americans.[38,55] However, the larger sample sizes of diverse cohorts reported here, 3-5 times larger
225 than previous, indicate that this is a robust and reproducible observation; that pTau-181 can be
226 incorporated in more diverse populations as a potential aide in diagnostic prediction. However, it is clear
227 that this biomarker lacks complete discrimination of status as there is significant overlap in individual
228 values between AD, MCI, and CU. This suggests that pTau-181 should be combined with other clinical
229 tests and existing risk factors in making diagnostic decisions or could be used as longitudinal measure of
230 rate of change in progression toward dementia.

231 While pTau-181 was significantly higher in AD than MCI or CU across the diverse cohorts
232 investigated, there was a range of discriminatory AOC values represented. Notably in the Peruvian

233 cohort, the overall AROC value was lower (0.64) than in the other cohorts. The underlying reason for this
234 cannot be determined, though given the higher overall pTau-181 levels in Peruvian CU is likely to affect
235 this analysis. Intriguingly, this may be related to admixture of genetic ancestries altering the utility of
236 biomarkers in these cohorts. Further investigation related to the complex interplay between genetics,
237 social and environmental determinants of health, and AD biomarkers will be critical to continue to assess
238 these questions.

239 Overall, we provide further evidence that AD plasma biomarkers, particularly pTau-181,
240 can be used to discriminate between AD and MCI or CU not only in NHW populations but in
241 ancestrally diverse cohorts. We have added significantly to the ongoing research in this area
242 while greatly increasing the inclusivity of individuals that have traditionally made up only a very
243 small proportion of participants in biomarker studies. Further confirmation of these observations
244 in diverse cohorts including either autopsy confirmed individuals or those with extensive
245 diagnostic imaging could provide further validation of the use of these biomarkers in clinical
246 based cohorts while assisting in establishing ancestry specific cut-points for diagnostic purposes.
247 Ultimately, adding in AD plasma biomarkers with genetic and environmental information in
248 these diverse populations will continue to reveal the general and ancestry specific risk profile of
249 AD aiding in development of precision treatment strategies.

250

251 **References**

- 252 [1] 2023 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* 2023;19:1598-1695.
- 253 [2] G. Sirugo, S.M. Williams, S.A. Tishkoff, The Missing Diversity in Human Genetic Studies. *Cell*
254 2019;177:26-31.
- 255 [3] G.W. Beecham, B. Vardarajan, E. Blue, W. Bush, J. Jaworski, S. Barral, A. DeStefano, K. Hamilton-
256 Nelson, B. Kunkle, E.R. Martin, A. Naj, F. Rajabli, C. Reitz, T. Thornton, C. van Duijn, A. Goate, S.
257 Seshadri, L.A. Farrer, E. Boerwinkle, G. Schellenberg, J.L. Haines, E. Wijsman, R. Mayeux, M.A.
258 Pericak-Vance, Alzheimer's Disease Sequencing Project, Rare genetic variation implicated in non-
259 Hispanic white families with Alzheimer disease. *Neurol Genet* 2018;4:e286.
- 260 [4] J.C. Bis, X. Jian, B.W. Kunkle, Y. Chen, K.L. Hamilton-Nelson, W.S. Bush, W.J. Salerno, D.
261 Lancour, Y. Ma, A.E. Renton, E. Marcora, J.J. Farrell, Y. Zhao, L. Qu, S. Ahmad, N. Amin, P. Amouyel,
262 G.W. Beecham, J.E. Below, D. Champion, C. Charbonnier, J. Chung, P.K. Crane, C. Cruchaga, L.A.
263 Cupples, J.F. Dartigues, S. Debette, J.F. Deleuze, L. Fulton, S.B. Gabriel, E. Genin, R.A. Gibbs, A.
264 Goate, B. Grenier-Boley, N. Gupta, J.L. Haines, A.S. Havulinna, S. Helisalmi, M. Hiltunen, D.P.
265 Howrigan, M.A. Ikram, J. Kaprio, J. Konrad, A. Kuzma, E.S. Lander, M. Lathrop, T. Lehtimaki, H. Lin,
266 K. Mattila, R. Mayeux, D.M. Muzny, W. Nasser, B. Neale, K. Nho, G. Nicolas, D. Patel, M.A. Pericak-
267 Vance, M. Perola, B.M. Psaty, O. Quenez, F. Rajabli, R. Redon, C. Reitz, A.M. Remes, V. Salomaa, C.
268 Sarnowski, H. Schmidt, M. Schmidt, R. Schmidt, H. Soininen, T.A. Thornton, G. Tosto, C. Tzourio, S.J.
269 van der Lee, C.M. van Duijn, B. Vardarajan, W. Wang, E. Wijsman, R.K. Wilson, D. Witten, K.C.
270 Worley, X. Zhang, Alzheimer's Disease Sequencing Project, C. Bellenguez, J.C. Lambert, M.I. Kurki, A.
271 Palotie, M. Daly, E. Boerwinkle, K.L. Lunetta, A.L. Destefano, J. Dupuis, E.R. Martin, G.D.
272 Schellenberg, S. Seshadri, A.C. Naj, M. Fornage, L.A. Farrer, Whole exome sequencing study identifies
273 novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional
274 regulation. *Mol Psychiatry* 2018.
- 275 [5] B.N. Vardarajan, S. Barral, J. Jaworski, G.W. Beecham, E. Blue, G. Tosto, D. Reyes-Dumeyer, M.
276 Medrano, R. Lantigua, A. Naj, T. Thornton, A. DeStefano, E. Martin, L.S. Wang, L. Brown, W. Bush, C.
277 van Duijn, A. Goate, L. Farrer, J.L. Haines, E. Boerwinkle, G. Schellenberg, E. Wijsman, M.A. Pericak-
278 Vance, R. Mayeux, Alzheimer's Disease Sequencing Project, L.S. Wang, Whole genome sequencing of
279 Caribbean Hispanic families with late-onset Alzheimer's disease. *Ann Clin Transl Neurol* 2018;5:406-
280 417.
- 281 [6] B.W. Kunkle, B. Grenier-Boley, R. Sims, J.C. Bis, V. Damotte, A.C. Naj, A. Boland, M. Vronskaya,
282 S.J. van der Lee, A. Amlie-Wolf, C. Bellenguez, A. Frizatti, V. Chouraki, E.R. Martin, K. Sleegers, N.
283 Badarinarayan, J. Jakobsdottir, K.L. Hamilton-Nelson, S. Moreno-Grau, R. Olaso, R. Raybould, Y. Chen,
284 A.B. Kuzma, M. Hiltunen, T. Morgan, S. Ahmad, B.N. Vardarajan, J. Epelbaum, P. Hoffmann, M.
285 Boada, G.W. Beecham, J.G. Garnier, D. Harold, A.L. Fitzpatrick, O. Valladares, M.L. Moutet, A.
286 Gerrish, A.V. Smith, L. Qu, D. Bacq, N. Denning, X. Jian, Y. Zhao, M. Del Zompo, N.C. Fox, S.H. Choi,
287 I. Mateo, J.T. Hughes, H.H. Adams, J. Malamon, F. Sanchez-Garcia, Y. Patel, J.A. Brody, B.A.
288 Dombroski, M.C.D. Naranjo, M. Daniilidou, G. Eiriksdottir, S. Mukherjee, D. Wallon, J. Uphill, T.
289 Aspelund, L.B. Cantwell, F. Garzia, D. Galimberti, E. Hofer, M. Butkiewicz, B. Fin, E. Scarpini, C.
290 Sarnowski, W.S. Bush, S. Meslage, J. Kornhuber, C.C. White, Y. Song, R.C. Barber, S. Engelborghs, S.
291 Sordon, D. Voijnovic, P.M. Adams, R. Vandenberghe, M. Mayhaus, L.A. Cupples, M.S. Albert, P.P. De
292 Deyn, W. Gu, J.J. Himali, D. Beekly, A. Squassina, A.M. Hartmann, A. Orellana, D. Blacker, E.
293 Rodriguez-Rodriguez, S. Lovestone, M.E. Garcia, R.S. Doody, C. Munoz-Fernandez, R. Sussams, H. Lin,
294 T.J. Fairchild, Y.A. Benito, C. Holmes, H. Karamujic-Comic, M.P. Frosch, H. Thonberg, W. Maier, G.

295 Roschupkin, B. Ghetti, V. Giedraitis, A. Kawalia, S. Li, R.M. Huebinger, L. Kilander, S. Moebus, I.
296 Hernandez, M.I. Kamboh, R. Brundin, J. Turton, Q. Yang, M.J. Katz, L. Concari, J. Lord, A.S. Beiser,
297 C.D. Keene, S. Helisalimi, I. Kloszewska, W.A. Kukull, A.M. Koivisto, A. Lynch, L. Tarraga, E.B.
298 Larson, A. Haapasalo, B. Lawlor, T.H. Mosley, R.B. Lipton, V. Solfrizzi, M. Gill, W.T. Longstreth Jr,
299 T.J. Montine, V. Frisardi, M. Diez-Fairen, F. Rivadeneira, R.C. Petersen, V. Deramecourt, I. Alvarez, F.
300 Salani, A. Ciaramella, E. Boerwinkle, E.M. Reiman, N. Fievet, J.I. Rotter, J.S. Reisch, O. Hanon, C.
301 Cupidi, A.G. Andre Uitterlinden, D.R. Royall, C. Dufouil, R.G. Maletta, I. de Rojas, M. Sano, A. Brice,
302 R. Cecchetti, P.S. George-Hyslop, K. Ritchie, M. Tzolaki, D.W. Tsuang, B. Dubois, D. Craig, C.K. Wu,
303 H. Soininen, D. Avramidou, R.L. Albin, L. Fratiglioni, A. Germanou, L.G. Apostolova, L. Keller, M.
304 Koutroumani, S.E. Arnold, F. Panza, O. Gkatzima, S. Asthana, D. Hannequin, P. Whitehead, C.S.
305 Atwood, P. Caffarra, H. Hampel, I. Quintela, A. Carracedo, L. Lannfelt, D.C. Rubinsztein, L.L. Barnes,
306 F. Pasquier, L. Frolich, S. Barral, B. McGuinness, T.G. Beach, J.A. Johnston, J.T. Becker, P. Passmore,
307 E.H. Bigio, J.M. Schott, T.D. Bird, J.D. Warren, B.F. Boeve, M.K. Lupton, J.D. Bowen, P. Proitsi, A.
308 Boxer, J.F. Powell, J.R. Burke, J.S.K. Kauwe, J.M. Burns, M. Mancuso, J.D. Buxbaum, U. Bonuccelli,
309 N.J. Cairns, A. McQuillin, C. Cao, G. Livingston, C.S. Carlson, N.J. Bass, C.M. Carlsson, J. Hardy, R.M.
310 Carney, J. Bras, M.M. Carrasquillo, R. Guerreiro, M. Allen, H.C. Chui, E. Fisher, C. Masullo, E.A.
311 Crocco, C. DeCarli, G. Bisceglia, M. Dick, L. Ma, R. Duara, N.R. Graff-Radford, D.A. Evans, A.
312 Hodges, K.M. Faber, M. Scherer, K.B. Fallon, M. Riemenschneider, D.W. Fardo, R. Heun, M.R. Farlow,
313 H. Kolsch, S. Ferris, M. Leber, T.M. Foroud, I. Heuser, D.R. Galasko, I. Giegling, M. Gearing, M. Hull,
314 D.H. Geschwind, J.R. Gilbert, J. Morris, R.C. Green, K. Mayo, J.H. Growdon, T. Feulner, R.L. Hamilton,
315 L.E. Harrell, D. Drichel, L.S. Honig, T.D. Cushion, M.J. Huentelman, P. Hollingworth, C.M. Hulette,
316 B.T. Hyman, R. Marshall, G.P. Jarvik, A. Meggy, E. Abner, G.E. Menzies, L.W. Jin, G. Leonenko, L.M.
317 Real, G.R. Jun, C.T. Baldwin, D. Grozeva, A. Karydas, G. Russo, J.A. Kaye, R. Kim, F. Jessen, N.W.
318 Kowall, B. Vellas, J.H. Kramer, E. Vardy, F.M. LaFerla, K.H. Jockel, J.J. Lah, M. Dichgans, J.B.
319 Leverenz, D. Mann, A.I. Levey, S. Pickering-Brown, A.P. Lieberman, N. Klopp, K.L. Lunetta, H.E.
320 Wichmann, C.G. Lyketsos, K. Morgan, D.C. Marson, K. Brown, F. Martiniuk, C. Medway, D.C. Mash,
321 M.M. Nothen, E. Masliah, N.M. Hooper, W.C. McCormick, A. Daniele, S.M. McCurry, A. Bayer, A.N.
322 McDavid, J. Gallacher, A.C. McKee, H. van den Bussche, M. Mesulam, C. Brayne, B.L. Miller, S.
323 Riedel-Heller, C.A. Miller, J.W. Miller, A. Al-Chalabi, J.C. Morris, C.E. Shaw, A.J. Myers, J. Wiltfang,
324 S. O'Bryant, J.M. Olichney, V. Alvarez, J.E. Parisi, A.B. Singleton, H.L. Paulson, J. Collinge, W.R.
325 Perry, S. Mead, E. Peskind, D.H. Cribbs, M. Rossor, A. Pierce, N.S. Ryan, W.W. Poon, B. Nacmias, H.
326 Potter, S. Sorbi, J.F. Quinn, E. Sacchinelli, A. Raj, G. Spalletta, M. Raskind, C. Caltagirone, P. Bossu,
327 M.D. Orfei, B. Reisberg, R. Clarke, C. Reitz, A.D. Smith, J.M. Ringman, D. Warden, E.D. Roberson, G.
328 Wilcock, E. Rogaeva, A.C. Bruni, H.J. Rosen, M. Gallo, R.N. Rosenberg, Y. Ben-Shlomo, M.A. Sager, P.
329 Mecocci, A.J. Saykin, P. Pastor, M.L. Cuccaro, J.M. Vance, J.A. Schneider, L.S. Schneider, S. Slifer,
330 W.W. Seeley, A.G. Smith, J.A. Sonnen, S. Spina, R.A. Stern, R.H. Swerdlow, M. Tang, R.E. Tanzi, J.Q.
331 Trojanowski, J.C. Troncoso, V.M. Van Deerlin, L.J. Van Eldik, H.V. Vinters, J.P. Vonsattel, S.
332 Weintraub, K.A. Welsh-Bohmer, K.C. Wilhelmsen, J. Williamson, T.S. Wingo, R.L. Woltjer, C.B.
333 Wright, C.E. Yu, L. Yu, Y. Saba, (. Alzheimer Disease Genetics Consortium, (. European Alzheimer's
334 Disease Initiative, Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium,
335 (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental
336 Risk for Alzheimer's Disease Consortium (GERAD/PERADES), A. Pilotto, M.J. Bullido, O. Peters, P.K.
337 Crane, D. Bennett, P. Bosco, E. Coto, V. Boccardi, P.L. De Jager, A. Lleo, N. Warner, O.L. Lopez, M.
338 Ingelsson, P. Deloukas, C. Cruchaga, C. Graff, R. Gwilliam, M. Fornage, A.M. Goate, P. Sanchez-Juan,
339 P.G. Kehoe, N. Amin, N. Ertekin-Taner, C. Berr, S. Debette, S. Love, L.J. Launer, S.G. Younkin, J.F.
340 Dartigues, C. Corcoran, M.A. Ikram, D.W. Dickson, G. Nicolas, D. Champion, J. Tschanz, H. Schmidt, H.
341 Hakonarson, J. Clarimon, R. Munger, R. Schmidt, L.A. Farrer, C. Van Broeckhoven, M. C O'Donovan,
342 A.L. DeStefano, L. Jones, J.L. Haines, J.F. Deleuze, M.J. Owen, V. Gudnason, R. Mayeux, V. Escott-
343 Price, B.M. Psaty, A. Ramirez, L.S. Wang, A. Ruiz, C.M. van Duijn, P.A. Holmans, S. Seshadri, J.
344 Williams, P. Amouyel, G.D. Schellenberg, J.C. Lambert, M.A. Pericak-Vance, Genetic meta-analysis of

- 345 diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid
346 processing. *Nat Genet* 2019;51:414-430.
- 347 [7] V.B. Sheppard, L.S. Cox, M.J. Kanamori, J. Canar, Y. Rodriguez, M. Goodman, J. Pomeroy, J.
348 Mandelblatt, E.E. Huerta, Latin American Cancer Research Coalition, Brief report: if you build it, they
349 will come: methods for recruiting Latinos into cancer research. *J Gen Intern Med* 2005;20:444-447.
- 350 [8] J.L. Calderon, R.S. Baker, H. Fabrega, J.G. Conde, R.D. Hays, E. Fleming, K. Norris, An ethno-
351 medical perspective on research participation: a qualitative pilot study. *MedGenMed* 2006;8:23.
- 352 [9] V.L. Shavers, C.F. Lynch, L.F. Burmeister, Racial differences in factors that influence the willingness
353 to participate in medical research studies. *Ann Epidemiol* 2002;12:248-256.
- 354 [10] A.G. Ramirez, A.R. Miller, K. Gallion, S. San Miguel de Majors, P. Chalela, S. Garcia Aramburo,
355 Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and
356 their family members previously registered in local cancer registries in Texas. *Community Genet*
357 2008;11:215-223.
- 358 [11] D.J. Bowen, V.B. Penchaszadeh, Special issue: enhancing minority recruitment into genetics
359 research. *Community Genet* 2008;11:189-190.
- 360 [12] J. Jacobellis, G. Cutter, Mammography screening and differences in stage of disease by
361 race/ethnicity. *Am J Public Health* 2002;92:1144-1150.
- 362 [13] L. Rahib, M.R. Wehner, L.M. Matrisian, K.T. Nead, Estimated Projection of US Cancer Incidence
363 and Death to 2040. *JAMA Netw Open* 2021;4:e214708.
- 364 [14] J.W. Eley, H.A. Hill, V.W. Chen, D.F. Austin, M.N. Wesley, H.B. Muss, R.S. Greenberg, R.J.
365 Coates, P. Correa, C.K. Redmond, Racial differences in survival from breast cancer. Results of the
366 National Cancer Institute Black/White Cancer Survival Study. *Jama* 1994;272:947-954.
- 367 [15] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30.
- 368 [16] E.D. Paskett, C. Tatum, J. Rushing, R. Michielutte, R. Bell, K.L. Foley, M. Bittoni, S. Dickinson,
369 Racial differences in knowledge, attitudes, and cancer screening practices among a triracial rural
370 population. *Cancer* 2004;101:2650-2659.
- 371 [17] J.C. Lennon, S.L. Aita, V.A.D. Bene, T. Rhoads, Z.J. Resch, J.M. Eloi, K.A. Walker, Black and
372 White individuals differ in dementia prevalence, risk factors, and symptomatic presentation. *Alzheimers*
373 *Dement* 2022;18:1461-1471.
- 374 [18] M.X. Tang, G. Maestre, W.Y. Tsai, X.H. Liu, L. Feng, W.Y. Chung, M. Chun, P. Schofield, Y.
375 Stern, B. Tycko, R. Mayeux, Relative risk of Alzheimer disease and age-at-onset distributions, based on
376 APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. *Am J*
377 *Hum Genet* 1996;58:574-584.
- 378 [19] M.X. Tang, P. Cross, H. Andrews, D.M. Jacobs, S. Small, K. Bell, C. Merchant, R. Lantigua, R.
379 Costa, Y. Stern, R. Mayeux, Incidence of AD in African-Americans, Caribbean Hispanics, and
380 Caucasians in northern Manhattan. *Neurology* 2001;56:49-56.

- 381 [20] B.N. Vardarajan, K.M. Faber, T.D. Bird, D.A. Bennett, R. Rosenberg, B.F. Boeve, N.R. Graff-
382 Radford, A.M. Goate, M. Farlow, R.A. Sweet, R. Lantigua, M.Z. Medrano, R. Ottman, D.J. Schaid, T.M.
383 Foroud, R. Mayeux, NIA-LOAD/NCRAD Family Study Group, Age-specific incidence rates for
384 dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on
385 Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer
386 Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA).
387 *JAMA Neurol* 2014;71:315-323.
- 388 [21] G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr, C.H. Kawas, W.E. Klunk,
389 W.J. Koroshetz, J.J. Manly, R. Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. Scheltens, M.C.
390 Carrillo, B. Thies, S. Weintraub, C.H. Phelps, The diagnosis of dementia due to Alzheimer's disease:
391 recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
392 diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263-269.
- 393 [22] S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C.R. Jack, W. Jagust, J.Q. Trojanowski, A.W.
394 Toga, L. Beckett, Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease
395 Neuroimaging Initiative (ADNI). *Alzheimers Dement* 2005;1:55-66.
- 396 [23] I.S. van Maurik, S.J. Vos, I. Bos, F.H. Bouwman, C.E. Teunissen, P. Scheltens, F. Barkhof, L.
397 Frolich, J. Kornhuber, J. Wiltfang, W. Maier, O. Peters, E. Ruther, F. Nobili, G.B. Frisoni, L. Spira, Y.
398 Freund-Levi, A.K. Wallin, H. Hampel, H. Soininen, M. Tsolaki, F. Verhey, I. Kloszewska, P. Mecocci,
399 B. Vellas, S. Lovestone, S. Galluzzi, S. Herukka, I. Santana, I. Baldeiras, A. de Mendonca, D. Silva, G.
400 Chetelat, S. Egret, S. Palmqvist, O. Hansson, P.J. Visser, J. Berkhof, W.M. van der Flier, Alzheimer's
401 Disease Neuroimaging Initiative, Biomarker-based prognosis for people with mild cognitive impairment
402 (ABIDE): a modelling study. *Lancet Neurol* 2019;18:1034-1044.
- 403 [24] S.E. O'Bryant, M.M. Mielke, R.A. Rissman, S. Lista, H. Vanderstichele, H. Zetterberg, P. Lewczuk,
404 H. Posner, J. Hall, L. Johnson, Y. Fong, J. Luthman, A. Jeromin, R. Batrla-Utermann, A. Villarreal, G.
405 Britton, P.J. Snyder, K. Henriksen, P. Grammas, V. Gupta, R. Martins, H. Hampel, Biofluid Based
406 Biomarker Professional Interest Area, Blood-based biomarkers in Alzheimer disease: Current state of the
407 science and a novel collaborative paradigm for advancing from discovery to clinic. *Alzheimers Dement*
408 2017;13:45-58.
- 409 [25] S.E. Schindler, J.G. Bollinger, V. Ovod, K.G. Mawuenyega, Y. Li, B.A. Gordon, D.M. Holtzman,
410 J.C. Morris, T.L.S. Benzinger, C. Xiong, A.M. Fagan, R.J. Bateman, High-precision plasma beta-amyloid
411 42/40 predicts current and future brain amyloidosis. *Neurology* 2019;93:e1647-e1659.
- 412 [26] T.K. Karikari, T.A. Pascoal, N.J. Ashton, S. Janelidze, A.L. Benedet, J.L. Rodriguez, M. Chamoun,
413 M. Savard, M.S. Kang, J. Therriault, M. Scholl, G. Massarweh, J.P. Soucy, K. Hoglund, G. Brinkmalm,
414 N. Mattsson, S. Palmqvist, S. Gauthier, E. Stomrud, H. Zetterberg, O. Hansson, P. Rosa-Neto, K.
415 Blennow, Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic
416 performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*
417 2020;19:422-433.
- 418 [27] S. Janelidze, N. Mattsson, S. Palmqvist, R. Smith, T.G. Beach, G.E. Serrano, X. Chai, N.K. Proctor,
419 U. Eichenlaub, H. Zetterberg, K. Blennow, E.M. Reiman, E. Stomrud, J.L. Dage, O. Hansson, Plasma P-
420 tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology
421 and longitudinal progression to Alzheimer's dementia. *Nat Med* 2020;26:379-386.

- 422 [28] A.G. Ramirez, A.R. Miller, K. Gallion, S. San Miguel de Majors, P. Chalela, S. Garcia Aramburo,
423 Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and
424 their family members previously registered in local cancer registries in Texas. *Community Genet*
425 2008;11:215-223.
- 426 [29] G. Sirugo, S.M. Williams, S.A. Tishkoff, The Missing Diversity in Human Genetic Studies. *Cell*
427 2019;177:1080.
- 428 [30] J.C. Morris, S.E. Schindler, L.M. McCue, K.L. Moulder, T.L.S. Benzinger, C. Cruchaga, A.M.
429 Fagan, E. Grant, B.A. Gordon, D.M. Holtzman, C. Xiong, Assessment of Racial Disparities in
430 Biomarkers for Alzheimer Disease. *JAMA Neurol* 2019;76:264-273.
- 431 [31] C.E. Gleason, M. Zuelsdorff, D.C. Gooding, A.J.H. Kind, A.L. Johnson, T.T. James, N.H. Lambrou,
432 M.F. Wyman, F.B. Ketchum, A. Gee, S.C. Johnson, B.B. Bendlin, H. Zetterberg, Alzheimer's disease
433 biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.
434 *Alzheimers Dement* 2022;18:1545-1564.
- 435 [32] K. Armstrong, E. Micco, A. Carney, J. Stopfer, M. Putt, Racial differences in the use of BRCA1/2
436 testing among women with a family history of breast or ovarian cancer. *Jama* 2005;293:1729-1736.
- 437 [33] L. Kessler, S. Domchek, J. Stopfer, C.H. Halbert, BRCA1 and BRCA2 risk perceptions among
438 African American women at increased risk for hereditary breast-ovarian cancer. *Community Genet*
439 2008;11:193-200.
- 440 [34] C. Ricker, V. Lagos, N. Feldman, S. Hiyama, S. Fuentes, V. Kumar, K. Gonzalez, M. Palomares, K.
441 Blazer, K. Lowstuter, D. MacDonald, J. Weitzel, If we build it ... will they come?--establishing a cancer
442 genetics services clinic for an underserved predominantly Latina cohort. *Journal of Genetic Counseling*
443 2006;15:505-514.
- 444 [35] L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd,
445 P. Borgen, L. Norton, K. Offit, Outcome of preventive surgery and screening for breast and ovarian
446 cancer in BRCA mutation carriers. *J Clin Oncol* 2002;20:1260-1268.
- 447 [36] C. Lerman, C. Hughes, J.L. Benkendorf, B. Biesecker, J. Kerner, J. Willison, N. Eads, D. Hadley, J.
448 Lynch, Racial differences in testing motivation and psychological distress following pretest education for
449 BRCA1 gene testing. *Cancer Epidemiology, Biomarkers & Prevention* 1999;8:361-367.
- 450 [37] K. Armstrong, B. Weber, J. Stopfer, K. Calzone, M. Putt, J. Coyne, J.S. Schwartz, Early use of
451 clinical BRCA1/2 testing: associations with race and breast cancer risk. *American Journal of Medical*
452 *Genetics.Part A* 2003;117A:154-160.
- 453 [38] K. Deniz, C.C.G. Ho, K.G. Malphrus, J.S. Reddy, T. Nguyen, T.P. Carnwath, J.E. Crook, J.A. Lucas,
454 N.R. Graff-Radford, M.M. Carrasquillo, N. Ertekin-Taner, Plasma Biomarkers of Alzheimer's Disease in
455 African Americans. *J Alzheimers Dis* 2021;79:323-334.
- 456 [39] A.M. Brickman, J.J. Manly, L.S. Honig, D. Sanchez, D. Reyes-Dumeyer, R.A. Lantigua, P.J. Lao, Y.
457 Stern, J.P. Vonsattel, A.F. Teich, D.C. Airey, N.K. Proctor, J.L. Dage, R. Mayeux, Plasma p-tau181, p-
458 tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
459 *Alzheimers Dement* 2021.

- 460 [40] Y. Gu, L.S. Honig, M.S. Kang, A. Bahl, D. Sanchez, D. Reyes-Dumeyer, J.J. Manly, J.L. Dage, R.A.
461 Lantigua, A.M. Brickman, B.N. Vardarajan, R. Mayeux, Risk of Alzheimer's disease is associated with
462 longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-
463 Inwood Columbia Aging Project (WHICAP) cohort. *Alzheimers Dement* 2024.
- 464 [41] M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, A. Gamst, D.M.
465 Holtzman, W.J. Jagust, R.C. Petersen, P.J. Snyder, M.C. Carrillo, B. Thies, C.H. Phelps, The diagnosis of
466 mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on
467 Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers*
468 *Dement* 2011;7:270-279.
- 469 [42] B. Croisile, S. Auriacombe, F. Etcharry-Bouyx, M. Vercelletto, National Institute on Aging (u.s.),
470 Alzheimer Association, The new 2011 recommendations of the National Institute on Aging and the
471 Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive
472 impairment, and dementia. *Rev Neurol (Paris)* 2012;168:471-482.
- 473 [43] M.P. Conomos, S.M. Gogarten, L. Brown, H. Chen, K. Rice, T. Sofer, T. Thornton, C. Yu,
474 GENESIS: GENetic ESTimation and Inference in Structured samples (GENESIS): Statistical methods for
475 analyzing genetic data from samples with population structure and/or relatedness. 2019;R package
476 version 2.14.3.
- 477 [44] A. Manichaikul, J.C. Mychaleckyj, S.S. Rich, K. Daly, M. Sale, W.M. Chen, Robust relationship
478 inference in genome-wide association studies. *Bioinformatics* 2010;26:2867-2873.
- 479 [45] L.L. Cavalli-Sforza, The Human Genome Diversity Project: past, present and future. *Nat Rev Genet*
480 2005;6:333-340.
- 481 [46] D.H. Alexander, J. Novembre, K. Lange, Fast model-based estimation of ancestry in unrelated
482 individuals. *Genome Res* 2009;19:1655-1664.
- 483 [47] D.H. Wilson, D.M. Rissin, C.W. Kan, D.R. Fournier, T. Piech, T.G. Campbell, R.E. Meyer, M.W.
484 Fishburn, C. Cabrera, P.P. Patel, E. Frew, Y. Chen, L. Chang, E.P. Ferrell, V. von Einem, W. McGuigan,
485 M. Reinhardt, H. Sayer, C. Vielsack, D.C. Duffy, The Simoa HD-1 Analyzer: A Novel Fully Automated
486 Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. *J Lab Autom*
487 2016;21:533-547.
- 488 [48] A. Kuznetsova, P.B. Brockhoff, R.H.B. Christensen, lmerTest Package: Tests in Linear Mixed
489 Effects Models. *Journal of Statistical Software* 2017;82:1-26.
- 490 [49] T. Hothorn, F. Bretz, P. Westfall, Simultaneous inference in general parametric models. *Biom J*
491 2008;50:346-363.
- 492 [50] R.V. Lenth, Least-Squares Means: The R Package lsmeans. *Journal of Statistical Software*
493 2016;69:1-33.
- 494 [51] X. Robin, N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J. Sanchez, M. Müller, pROC: an open-
495 source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011;12:77.
- 496 [52] A. Kassambara, Ggpubr: 'Ggplot2' Based Publication Ready Plots; 2020.

497 [53] S. Palmqvist, S. Janelidze, Y.T. Quiroz, H. Zetterberg, F. Lopera, E. Stomrud, Y. Su, Y. Chen, G.E.
498 Serrano, A. Leuzy, N. Mattsson-Carlgen, O. Strandberg, R. Smith, A. Villegas, D. Sepulveda-Falla, X.
499 Chai, N.K. Proctor, T.G. Beach, K. Blennow, J.L. Dage, E.M. Reiman, O. Hansson, Discriminative
500 Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *Jama*
501 2020;324:772-781.

502 [54] S. Janelidze, D. Bali, N.J. Ashton, N.R. Barthelemy, J. Vanbrabant, E. Stoops, E. Vanmechelen, Y.
503 He, A.O. Dolado, G. Triana-Baltzer, M.J. Pontecorvo, H. Zetterberg, H. Kolb, M. Vandijck, K. Blennow,
504 R.J. Bateman, O. Hansson, Head-to-head comparison of 10 plasma phospho-tau assays in prodromal
505 Alzheimer's disease. *Brain* 2023;146:1592-1601.

506 [55] J.R. Hall, M. Petersen, L. Johnson, S.E. O'Bryant, Characterizing Plasma Biomarkers of Alzheimer's
507 in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort. *Front Neurol*
508 2022;13:871947.

509

510 **Consent Statement**

511 All participants, or their proxy, provided written informed consent as part of the study protocols approved
512 by the site-specific Institutional Review Boards.

513 **Acknowledgements**

514 We acknowledge the participation of the individuals included in this study. Biomarker data was generated
515 in collaboration with the Center for Genome Technology (CGT) from the John P. Hussman Institute for
516 Human Genomics (HIHG).

517 **Funding**

518 This work was supported by the National Institutes of Health National Institute on Aging (grant numbers
519 AG070935 to A.J.G and AG072547, AG052410, AG070864, and AG074865 to M.A.P.V.)

520 **Conflict of Interest**

521 The authors declare no conflicts of interest.

522 **Key Words**

523 Alzheimer's disease; diverse ancestry; plasma biomarkers; tau; amyloid

524

525 **Figure Legends**

526 **Figure 1.** Global genomic ancestry analysis. **A)** Principal component analyses. Estimation of relationship
527 to ancestral reference groups from Human Genome Diversity Project (HGDP): Maroon = African, Green
528 = Amerindian, Yellow = East Asian, Blue = European, or each sample cohort: Light Green = Cuban
529 American, Violet = Peruvian, Red = Puerto Rican, Aqua = African American. **B)** Ancestral admixture
530 estimations. Each column on the X-axis represents one participant. Colors in each vertical line represent
531 the proportion of ancestral admixture. Red = African, Blue = European, Green = Amerindian, Yellow =
532 East Asian.

533 **Figure 2.** AD biomarker levels across ancestral groups African Americans, Peruvians, and Caribbean
534 Hispanics. **A)** pTau-181 in cognitively unimpaired. **B)** pTau-181 in AD. **C)** A β 42/A β 40 in cognitively
535 unimpaired. **D)** A β 42/A β 40 in AD. **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$, ns = not significant

536 **Figure 3.** Plasma pTau-181 comparison analysis. Comparisons of the pTau-181 concentration in clinical
537 diagnosis statuses of Alzheimer Disease (AD), mild cognitively impaired (MCI), or cognitively
538 unimpaired (CU) in: **A)** The overall combined cohort, **B)** African Americans, **C)** Peruvians, and **D)**
539 Caribbean Hispanics. Each point represents one individual's pTau-181 measurement. Concentrations are
540 shown as median \pm interquartile range, **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$, ns = not
541 significant

542 **Figure 4.** Plasma A β 42/A β 40 ratio comparison analysis. Comparisons of the A β 42/A β 40 ratio in clinical
543 diagnosis statuses of Alzheimer Disease (AD), mild cognitively impaired (MCI), or cognitively
544 unimpaired (CU) in: **A)** The overall combined cohort, **B)** African Americans, **C)** Peruvians, and **D)**
545 Caribbean Hispanics. Each point represents one individual's A β 42/A β 40 ratio. Ratios are shown as
546 median \pm interquartile range, * $p < 0.05$, ns = not significant


547 **Figure 5.** pTau-181 and A β 42/A β 40 ratio comparisons in African American plasma and serum analysis.
548 Comparisons of pTau-181 concentrations between serum and plasma in **A)** cognitively unimpaired (CU)
549 and **B)** Alzheimer Disease (AD). A β 42/A β 40 ratio between serum and plasma in **C)** cognitively

550 unimpaired (CU) and **D**) Alzheimer Disease (AD). Each point represents one individual's measurement.


551 Concentrations are shown as median \pm interquartile range. **** $p < 0.0001$, ** $p < 0.01$, * $p < 0.05$





552 **Figure 6.** Serum pTau-181 and A β 42/A β 40 ratio comparison analysis. Comparisons of the **A**) pTau 181
553 concentration and **B**) A β 42/A β 40 ratio in clinical diagnosis statuses of Alzheimer Disease (AD), mild
554 cognitively impaired (MCI), or cognitively unimpaired (CU) in a subset of African American individuals
555 for which plasma was not available. Each point represents one individual's measurement. Concentrations
556 are shown as median \pm interquartile range. **** $p < 0.0001$, ns – not significant.





557 **Figure 7.** Receiver operating characteristic (ROC) curves of plasma and serum biomarkers for the
558 classification of Alzheimer disease status in: **A**) The overall combined cohort, **B**) Caribbean Hispanics, **C**)
559 Peruvians, **D**) African Americans - plasma, **E**) African Americans - serum. Red lines represent pTau-181
560 alone, green lines A β 42/A β 40 ratio alone, and blue lines the combination of pTau-181 and A β 42/A β 40
561 ratio.











- HGDP reference**
- ◆ African
 - ◆ Amerindian
 - ◆ East Asian
 - ◆ European
- Sample cohort**
- Cuban American
 - Peruvian
 - Puerto Rican
 - African American




A. ptau-181 in CU**B. ptau-181 in AD****C. A β 42/A β 40 ratio in CU****D. A β 42/A β 40 ratio in AD**

A. All Samples**B. African American****C. Peruvian****D. Caribbean Hispanic**


A. All Samples**B. African American****C. Peruvian****D. Caribbean Hispanic**






A. ptau-181 in CU**B. ptau-181 in AD****C. A β 42/A β 40 ratio in CU****D. A β 42/A β 40 ratio in AD**

A. Serum pTau181 level



B. Serum A β 42/A β 40 ratio



A. All Samples**B. Caribbean Hispanic****C. Peruvian****D. African American - Plasma****E. African American - Serum**

— log₁₀ pTau181 — log₁₀ ratio of Aβ₄₂ to Aβ₄₀ — log₁₀ pTau181 and log₁₀ ratio of Aβ₄₂ to Aβ₄₀